Simultaneous Determination of Glibenclamide and Silymarin Released from Chitosan Microparticles by HPLC-ESI-MS Technique: Method Development and Validation.
HPLC-ESI-MS method development and validation
chitosan microparticles
glibenclamide
silymarin
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
11 Oct 2022
11 Oct 2022
Historique:
received:
12
09
2022
revised:
04
10
2022
accepted:
06
10
2022
entrez:
27
10
2022
pubmed:
28
10
2022
medline:
28
10
2022
Statut:
epublish
Résumé
The study aim was to develop and validate a high-performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-ESI-MS) method to simultaneously determine glibenclamide (Gli) and silymarin (Sil) released from chitosan (CS) microparticles in aqueous solutions. The CS microparticles were synthesized using an ionic gelation method, and their morphology, swelling degree, encapsulation efficiency and active substance release were investigated. Gli and Sil were loaded in different concentrations, and their identification and quantification were performed using the HPLC-ESI-MS method, which was further validated. The drugs' characteristic m/z was found in the higher intensity of retention time (Rt) (Gli, 8.909 min; Sil A, 5.41 min; and Sil B, 5.66 min). The method selectivity and precision are very good, and the blank solution proved no interference. The linearity of the answer function is very good for Sil A (R
Identifiants
pubmed: 36297600
pii: pharmaceutics14102164
doi: 10.3390/pharmaceutics14102164
pmc: PMC9611085
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Romanian Ministry of Education and Research, CNCS - UEFISCDI
ID : PN-III-P4-ID-PCE-2020-1523
Organisme : Romanian Ministry of Education and Research, CNCS - UEFISCDI
ID : project number PN-III-P4-ID-PCE-2020-2687, Contract no. 244/2021
Organisme : Acknowledgments: This work was supported by the research infrastructure developed through the European Social Fund for Regional Development, Competitiveness Operational Programme 2014-2020, Axis 1, Action: 1.1.3, Project "Infra SupraChem Lab - Center for
ID : Contract 339/390015/25.02.2021, cod MySMIS: 108983
Références
Can J Diabetes. 2018 Apr;42 Suppl 1:S10-S15
pubmed: 29650080
Aging Dis. 2018 Aug 1;9(4):685-695
pubmed: 30090656
Int J Mol Sci. 2022 May 25;23(11):
pubmed: 35682618
Sci Rep. 2017 Dec 18;7(1):17692
pubmed: 29255209
Endocr Rev. 2016 Jun;37(3):278-316
pubmed: 27159875
Diabetes Res Clin Pract. 2019 Nov;157:107843
pubmed: 31518657
Int J Biol Macromol. 2014 Sep;70:20-5
pubmed: 24971559
Int J Biol Macromol. 2015 Jan;72:1069-75
pubmed: 25312603
Molecules. 2019 Apr 19;24(8):
pubmed: 31010179
J Med Food. 2007 Sep;10(3):543-7
pubmed: 17887949
Molecules. 2017 Jan 24;22(2):
pubmed: 28125040
Diabetes Res Clin Pract. 2011 Mar;91(3):265-70
pubmed: 20832133
Adv Food Nutr Res. 2014;73:33-44
pubmed: 25300541
Physiology (Bethesda). 2018 Mar 1;33(2):138-150
pubmed: 29412061
Exp Clin Endocrinol Diabetes. 2019 Dec;127(S 01):S73-S92
pubmed: 31860927
J Pharmacol Pharmacother. 2011 Oct;2(4):287-9
pubmed: 22025861
Nat Rev Endocrinol. 2016 Oct;12(10):616-22
pubmed: 27388988
Nat Commun. 2018 Apr 24;9(1):1620
pubmed: 29693652
Materials (Basel). 2019 Feb 13;12(4):
pubmed: 30781782
Arch Med Sci. 2012 Nov 9;8(5):899-906
pubmed: 23185202
Adv Ther. 2020 Apr;37(4):1279-1301
pubmed: 32065376
Diabetes Ther. 2013 Dec;4(2):195-220
pubmed: 24142577
Can Fam Physician. 2018 Apr;64(4):295
pubmed: 29650607
Arch Med Sci. 2015 Aug 12;11(4):840-8
pubmed: 26322096
Curr Clin Pharmacol. 2012 Aug;7(3):214-28
pubmed: 22432846
Clin Diabetes. 2015 Oct;33(4):175-80
pubmed: 26487791
World J Gastroenterol. 2017 Jul 21;23(27):5004-5017
pubmed: 28785154
Int J Biol Macromol. 2022 Feb 15;198:101-110
pubmed: 34968533
Int J Cardiol. 2019 Sep 15;291:29-35
pubmed: 30833106
Polymers (Basel). 2021 Sep 24;13(19):
pubmed: 34641071
Int J Biol Macromol. 2021 Jul 1;182:730-742
pubmed: 33836191